Lymphoid Tumor panel (CD3, CD20, Ki-67) Test

Lymphoma panels provide dominant and clinically validated tools for the molecular classification of lymphomas. The panel present in it show clinically actionable gene mutations present in the most common types of B-cell lymphomas. These panels of lymphoma have been used to power several clinical trials with biopharmaceutical companies and are also available for clinical diagnostic work-up, management and treatment selection in lymphoma patients. The Lymphoma panel is also available to detect mutations in 220 selected genes under investigation in Lymphomas.

Progression to disperse large B-cell lymphoma/DLBCL (Richter’s transformation) and to Hodgkin lymphoma can often be established by a high growth fraction in the past and the appearance of Hodgkin markers such as CD15 and CD30 as well as EBV in the later project. Richter’s transformation of CLL with Hodgkin-like cells has also been linked with EBV. Immunodeficiency connected with Fludarabine therapy for CLL has also been related to EBV positive B-cell proliferation that can resemble DLBCL. Examples of CLL with well-known and often large proliferation centers may raise concern for progression to DLBCL but a high growth fraction will be confined to the proliferation centers indifference to the more diffuse Ki-67 labeling in Richter’s conversion. Prolymphocytic revolution is determined by the prolymphocyte count in the secondary blood.

Application of immunohistochemistry is required in the diagnosis of non-Hodgkin whereas the diagnosis of lymphoid tumors relies heavily on the determination of cell lineage.

The initial studies with Rituximab therapy show less activity in small lymphocytic lymphoma than in other B-cell malignancies because of the lower CD20 antigen thickness on these lymphoma cells, succeeding studies showed that higher doses of Rituximab could overcome this problem as well as the extra problem of shedding of the CD20 antigen into the plasma in CLL patients. Documenting the appearance of this antigen can consequently help in setting up therapeutic options for the patient.